These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 23890370)

  • 1. Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up.
    Gianotti N; Galli L; Salpietro S; Cernuschi M; Bossolasco S; Maillard M; Spagnuolo V; Canducci F; Clementi M; Lazzarin A; Castagna A
    Clin Microbiol Infect; 2013 Dec; 19(12):E542-4. PubMed ID: 23890370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL.
    Gianotti N; Galli L; Racca S; Salpietro S; Cossarini F; Spagnuolo V; Barda B; Canducci F; Clementi M; Lazzarin A; Castagna A
    J Antimicrob Chemother; 2012 Jan; 67(1):213-7. PubMed ID: 21987242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients.
    Gianotti N; Canducci F; Galli L; Cossarini F; Salpietro S; Poli A; Nozza S; Spagnuolo V; Clementi M; Sampaolo M; Ceresola ER; Racca S; Lazzarin A; Castagna A
    Clin Microbiol Infect; 2015 Jan; 21(1):103.e7-103.e10. PubMed ID: 25636935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
    Havlir DV; Koelsch KK; Strain MC; Margot N; Lu B; Ignacio CC; Miller MD; Wong JK;
    J Infect Dis; 2005 Apr; 191(7):1164-8. PubMed ID: 15747253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.
    Bonora S; Nicastri E; Calcagno A; Gonzalez de Requena D; D'Ettorre G; Sarmati L; Palmisano L; Vullo V; Di Perri G; Andreoni M
    J Med Virol; 2009 Mar; 81(3):400-5. PubMed ID: 19152404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
    Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
    HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Sungkanuparph S; Groger RK; Overton ET; Fraser VJ; Powderly WG
    HIV Med; 2006 Oct; 7(7):437-41. PubMed ID: 16925729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.
    Miller V; Staszewski S; Sabin C; Carlebach A; Rottmann C; Weidmann E; Rabenau H; Hill A; Lepri AC; Phillips AN
    J Infect Dis; 1999 Aug; 180(2):530-3. PubMed ID: 10395876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Very Low Level Viremia Is Associated with Virological Failure in Highly Active Antiretroviral Treatment-Treated Patients.
    Calcagno A; Motta I; Ghisetti V; Lo Re S; Allice T; Marinaro L; Milia MG; Tettoni MC; Trentini L; Orofino G; Salassa B; Di Perri G; Bonora S
    AIDS Res Hum Retroviruses; 2015 Oct; 31(10):999-1008. PubMed ID: 26165150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
    Marcelin AG; Delaugerre C; Beaudoux C; Descamps D; Morand-Joubert L; Amiel C; Schneider V; Ferre V; Izopet J; Si-Mohamed A; Maillard A; Henquell C; Desbois D; Lazrek M; Signori-Schmuck A; Rogez S; Yerly S; Trabaud MA; Plantier JC; Fourati S; Houssaini A; Masquelier B; Calvez V; Flandre P;
    Int J Antimicrob Agents; 2013 Jul; 42(1):42-7. PubMed ID: 23562640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain.
    Sarmati L; Parisi SG; Montano M; Andreis S; Scaggiante R; Galgani A; Viscione M; Maffongelli G; Ricciardi A; Andreoni C; Boros S; Palù G; Andreoni M
    J Antimicrob Chemother; 2012 Dec; 67(12):2932-8. PubMed ID: 22915460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
    Pernas B; Grandal M; Pertega S; Cañizares A; Castro-Iglesias Á; Mena Á; Rodriguez-Osorio I; Tabernilla A; Pedreira JD; Poveda E
    J Antimicrob Chemother; 2016 Apr; 71(4):1051-5. PubMed ID: 26702924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
    Phillips AN; Staszewski S; Lampe F; Youle MS; Klauke S; Bickel M; Sabin CA; Doerr HW; Johnson MA; Loveday C; Miller V; ;
    J Infect Dis; 2002 Oct; 186(8):1086-91. PubMed ID: 12355358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients.
    Petrara MR; Cattelan AM; Zanchetta M; Sasset L; Freguja R; Gianesin K; Cecchetto MG; Carmona F; De Rossi A
    J Clin Virol; 2012 Mar; 53(3):195-200. PubMed ID: 22209290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.